Contrast Enhanced MRI of the Prostate

Completed

Conditions studied: Prostatic Neoplasms

In brief

Prostate cancer detection and disease progression monitoring relies on systematic multi-core biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly needed. The purpose of this study is to determine if a new MRI technique can identify and monitor prostate disease progression. If so biopsy core number can be reduced to as small as one, and frequency for biopsy repeat can be reduced. The new technique is about a new way of analyzing the pictures taken as part of prostate MRI exam. This part is called dynamic contrast-enhanced MRI. It involves an injection of contrast reagent (or dye) through the arm vein during a time period when prostate MRI pictures are continuously taken.

Key facts

Study ID

NCT02245282

Run by

OHSU Knight Cancer Institute

People needed

14

Starts

2017-02-10

Expected to finish

2018-12-12

Last updated by the study team

2020-09-17

Who can join

Age: 18 and older, up to 75. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men, age >18 years.
• Any patient scheduled for prostate biopsy repeat or radical prostatectomy.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Patients who would be normally excluded from undergoing an MRI examination - patients with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field.
• Patients who are unable to cooperate for an MRI exam.
• Major surgery within a month of enrollment.
• Prostate biopsy six weeks prior to enrollment.
• Subject-reported reaction to gadolinium contrast reagent.

Where it is running

• Advanced Imaging Research Center, OHSU — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.